Skip to main content

#156531

Anti-CD200 ligand [OX102]

Cat. #156531

Anti-CD200 ligand [OX102]

Cat. #: 156531

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 10-12 weeks

Target: CD200 ligand

Class: Monoclonal

Application: FACS ; IHC

Reactivity: Rat

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Institute: Medical Research Council; University of Oxford

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-CD200 ligand [OX102]
  • Research fields: Immunology
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Reactivity: Rat
  • Host: Mouse
  • Application: FACS ; IHC
  • Description: Recognises CD200 ligand, 60-100kD cell surface molecule expressed by cells of myeloid lineage (not T or B lymphocytes). Antibody can block CD200 interaction with CD200R.
  • Immunogen: Biotinylated rat (AO) thymocytes
  • Myeloma used: NS1
  • Recommended controls: IgG1

Target Details

  • Target: CD200 ligand
  • Tissue cell line specificity: IgG1
  • Target background: Recognises CD200 ligand, 60-100kD cell surface molecule expressed by cells of myeloid lineage (not T or B lymphocytes). Antibody can block CD200 interaction with CD200R.

Applications

  • Application: FACS ; IHC

Handling

  • Format: Liquid
  • Unit size: 100 ug
  • Shipping conditions: Dry ice

References

  • Wright et al. 2000. Immunity. 13(2):233-42. PMID: 10981966.

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.